Navigation Links
Chemo Drug Improves Stomach Cancer Survival for Japanese Patients
Date:10/31/2007

Researchers aren't sure if drug would have same benefit for Caucasians

WEDNESDAY, Oct. 31 (HealthDay News) -- Treatment of stomach cancer with an experimental chemotherapy drug after surgery improved survival rates for Japanese patients, a new study found.

The results of the trial won't mean much for Americans with stomach cancer, because the drug, designated S-1, is classified as "investigational" in the United States. But the study results could add impetus to the use of drug and/or radiation therapy against stomach cancer, U.S. experts said.

"This is the third large study that demonstrates a significant benefit of adjuvant (combination) therapy either before or after surgery for gastric cancer," said Dr. Manish Shah, an assistant attending oncologist at Memorial Sloan-Kettering Cancer Center in New York City.

Until relatively recently, it had generally been thought that drug or radiation therapy for stomach cancer wouldn't accomplish much, Shah said. "With less than one-year survival with metastatic disease, there may have been a sense that it didn't do any good," he said.

Metastatic means that the gastric cancer has spread outside the stomach, establishing microscopic colonies beyond the reach of surgery. But the almost 1,060 participants in the Japanese trial were potentially curable with surgery, because the disease had not spread. Half were assigned S-1 treatment plus surgery, while the other half had surgery followed by observation alone.

The trial, scheduled to last three years, was stopped after 12 months, because the survival rate for the S-1 group was 80.1 percent, compared to 70.1 percent for the surgery-only group.

The findings are published in the Nov. 1 issue of the New England Journal of Medicine.

S-1 had been used in some U.S. trials but was abandoned because of the high rate of side effects, Shah said. Japanese people apparently metabolize the drug differently than Caucasians, minimizing its side effects, he said.

Other drugs are being used successfully against stomach cancer, as is radiation, said Dr. Jaffer Ajani, professor of medicine at the University of Texas M.D. Anderson Cancer Center in Houston. But surgery is the essential first step in treatment of stomach cancer, he said.

"Chemotherapy alone has never been shown to be beneficial," Ajani said.

The U.S. National Cancer Institute estimates that there are 21,260 new cases of stomach cancer among Americans each year, with 11,210 deaths.

"Treatment for my patients includes radiation and chemotherapy together," Ajani said. "Not for every patient, but for most patients."

Use of such adjuvant therapy for stomach cancer began slowly, with studies showing that "chemotherapy was better than not for patients with metastatic disease," Shah said. Later trials showed benefits for people whose cancers had not spread.

"For gastric cancer, since 2001, some kind of adjuvant therapy has been given here in the United States, along with radiation," Shah said.

More information

Complete information on stomach cancer is available from the U.S. National Cancer Institute.



SOURCES: Manish Shah, M.D., assistant attending oncologist, Memorial Sloan-Kettering Cancer Center, New York City; Jaffer Ajani, M.D., professor of medicine, University of Texas M.D. Anderson Cancer Center, Houston; Nov. 1, 2007, New England Journal of Medicine


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Acupuncture May Help Chemotherapy Side Effects
2. Chemotherapy Pill Has Fewer Side Effects Than IV
3. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
4. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
5. Therapy Boosts Chemotherapy Effects
6. Chemotherapy Effective for Bladder Cancer
7. Hope for Chemo-Resistant Leukemia Patients
8. New Method Of Delivering Chemotherapy
9. Drug That Is Found To Reduce Heart Damage from Chemo
10. The Benefits Of Chemotherapy For Women With Ovarian Cancer
11. New Compound Could Strengthen The Effect Of Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Chemo Drug Improves Stomach Cancer Survival for Japanese Patients
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: